Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

Journal of Patient-Reported Outcomes

Table 5 Time to first recorded improvement in the functional domains, Global Health Scale/Quality of Life and body image domains. Patients with no score at randomization and patients with high functioning as well as good GHS/QoL and body image at randomization were excluded from this analysis since high/good score at randomization leaves no room for improvement

	Kd maintenance group		Observation group		Hazard ratio (95%CI)	P-value
	Patients included in the analysis (n)	Improved n (%)	Patients included in the analysis (n)	Improved n (%)	Hazard ratio (95%CI)	P-value
Global Health scale/QoL	52	24 (46)	46	17 (37)	1.42 (0.73–2.76)	0.30
Physical functioning	40	15 (38)	43	15 (35)	1.03 (0.47–2.26)	0.94
Role functioning	48	31 (65)	53	38 (72)	0.83 (0.49–1.40)	0.49
Emotional functioning	32	10 (31)	22	10 (45)	0.66 (0.25–1.74)	0.40
Social functioning	39	23 (59)	40	23 (58)	0.95 (0.51–1.78)	0.88
Body image	48	34 (71)	42	32 (76)	0.86 (0.51–1.45)	0.58
Future perspectives	59	30 (51)	62	32 (52)	0.91 (0.52–1.59)	0.74